Tyson Foods Inc. has signed a definitive deal to purchase Hillshire Brands Co. for $7.75 billion, two days after the maker of Jimmy Dean sausages and Ball Park hot dogs was let out of its agreement to buy Pinnacle Foods.
The demand for portable, easy-to-eat foods has been growing, and Hormel isn't the only company hoping that can include liquid food that comes in the convenience bottle.
Brynwood Partners says it plans to leverage the 37-year-old brand's nutritional attributes and make changes to its packaging. Juicy Juice is in the 100 percent juice category.
Actavis has completed its $28 billion acquisition of fellow drugmaker Forest Laboratories, and the leader of the acquired company is now the CEO of Actavis.
Hormel Foods is buying Muscle Milk maker CytoSport for approximately $450 million, a move that will diversify its business and tap into younger consumers' demand for sports nutrition products.
Pinnacle Foods said it has scrapped its sale to Hillshire Brands, freeing Hillshire to be acquired by Tyson Foods.
Medical device maker Stryker said Monday it will buy bone and joint replacement maker Small Bone Innovations for up to $375 million in cash.
TreeHouse Foods is buying Flagstone Foods for $860 million as a way to gain access to the growing healthy snacks category.
Paint and coatings maker PPG Industries is buying Consorcio Comex SA de CV for $2.3 billion to help bolster its architectural coatings presence in Mexico and Central America.
Alcoa is delving deeper into the aerospace industry, spending nearly $3 billion to acquire the British jet engine component company Firth Rixson.
HanesBrands is buying DBApparel from Sun Capital Partners Inc. for about $550 million, giving the underwear and T-shirt company entry to the European market.
Software maker Oracle is buying Micros Systems Inc., which provides software and hardware to the hospitality and retail industries, for about $5.3 billion.
Dublin-based drugmaker Shire said it has rejected an unsolicited $46.2 billion offer from AbbVie Inc., arguing that it fundamentally undervalues the company and its prospects.
Alstom's chief executive says the French heavy engineering firm's agreement to sell off most of its power generation business to U.S. rival General Electric Co. will save jobs and protect France's national interests.
General Electric submitted a revised offer to buy the power generation business of France's Alstom that the American company hopes will be enough to win approval from the French government and see off a rival bid by Siemens.
Valeant, which is based in Canada, has teamed up with Bill Ackman's Pershing Square Capital Management to try to purchase Allergan. The two companies went public with their takeover attempt in April and have increased their offer several times.
The sound business plan, immaculate data models and clear timelines that supported the case for a merger all become theory once actual implementation begins.
Musk, chairman of the solar installer SolarCity, announced Tuesday that the company would acquire a solar panel maker and build factories "an order of magnitude" bigger than the plants that currently churn out panels.
Wal-Mart CEO Doug McMillon, who took the helm in February, vowed Wal-Mart would pick up the pace in technology in his address earlier this month at the company's annual shareholders meeting.
SanDisk is buying Fusion-io for about $1.1 billion as the flash-memory chip maker ramps up its storage business.
Engineering giants Siemens of Germany and Mitsubishi Heavy Industries of Japan on Monday jointly offered to buy parts of France's Alstom and start a long-term partnership, a move that could derail a competing bid by General Electric.
Hillshire Brands Co. is backing off of its offer to buy Pinnacle Foods Inc., a move that it needs to make in order for its $7.75 billion proposed deal with Tyson Foods to go through.
U.S. medical device manufacturer Medtronic announced Sunday night that it has agreed to buy Ireland-based competitor Covidien for $42.9 billion in cash and stock.
Valeant Pharmaceuticals aims to take its bid for Allergan to the Botox maker's shareholders after Allegan's board unanimously rejected its latest offer of about $53 billion.